Tsvetelina Lazarova

Dr. Lazarova has over 15 years of experience in organic chemistry, 10 of those in biotech in the Boston area. She was involved with 2 start-up companies. Dr. Lazarova received her B.A. degree in chemistry from Harvard University, M.A. in organic chemistry from MIT and PhD in organic Chemistry from University of California, Los Angeles. She studied with Profs. Stuart Schreiber, Stephen Buchwald and Michael E. Jung.

While at Enanta Pharmaceuticals, Dr. Lazarova initiated the chemistry portion of the immunology program and advanced two lead series to pre-clinical status as potential therapies for asthma and psoriasis. At Daiichi Asubio Research Laboratories, Dr. Lazarova led the nuclear hormone receptor project, which relied on structure guided drug design and rapid generation of focused libraries to develop novel cholesterol lowering agents.

Dr. Lazarova has also worked at ARIAD Pharmaceuticals (where she was the first chemist hired) where she worked with peptide mimetics involved in signal transduction pathways and on natural product analogs as potential protein transport inhibitors. At Cubist Pharmaceuticals, Dr. Lazarova designed and synthesized second generation analogs of Daptomycin (Cubicin TM), a novel lipopetide antibiotic used for the treatment of skin and soft tissue infections.